Inicio › Mieloma múltiple › Carolina del Norte › Charlotte
Ensayos clínicos de Mieloma múltiple en Charlotte, NC
21 estudios para Mieloma múltiple buscan participantes en centros de Charlotte y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutandoFase 3
- Research Site, Charlotte
- Research Site, Charlotte
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
ReclutandoFase 1
- Levine Cancer Institute, Charlotte
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
ReclutandoFase 2
- Atrium Health, Charlotte
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ReclutandoFase 3
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ReclutandoFase 4
- Levine Cancer Institute, Charlotte
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1/2
- Atrium Health Levine Cancer Institute, Charlotte
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutandoFase 2
- Atrium Health's Levine Cancer Institute, Charlotte
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ReclutandoFase 3
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
ReclutandoFase 1/2
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
ReclutandoFase 3
- Novant Health Cancer Institute, Charlotte
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ReclutandoFase 1
- Atrium Health, Levine Cancer Institute, Charlotte
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutandoFase 1/2
- Research Site, Charlotte
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ReclutandoFase 3
- Research Site, Charlotte
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
ReclutandoFase 1/2
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
Pre-malignant States to Hematologic Malignancies in Firefighters
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Levine Cancer Institute, Charlotte
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Atrium Health Levine Cancer, Charlotte
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ReclutandoFase 3
- Levine Cancer Institute, Charlotte
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
ReclutandoFase 2
- Levine Cancer Institute, Charlotte
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
ReclutandoFase 1/2
- Levine Cancer Institute, Charlotte
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
ReclutandoFase 3
- GSK Investigational Site, Charlotte
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 1
- Levine Cancer Institute, Charlotte
Más información sobre Mieloma múltiple en MedlinePlus
Ensayos de Mieloma múltiple en otras ciudades
- New York City, NY60 estudios
- Boston, MA42 estudios
- Atlanta, GA41 estudios
- Houston, TX38 estudios
- Durham, NC37 estudios
- Nashville, TN32 estudios
- Denver, CO27 estudios
- Rochester, MN24 estudios
- St. Louis, MO24 estudios
- Columbus, OH24 estudios
- Baldwin Park, CA23 estudios
- Chicago, IL22 estudios
Otros estudios en Charlotte
- Cáncer (todos los tipos)27 estudios
- Cáncer de seno22 estudios
- Cáncer de pulmón de células no pequeñas19 estudios
- Leucemia mielógena aguda16 estudios
- Obesidad16 estudios
- Sobrepeso15 estudios
- Cáncer del colon y del recto13 estudios
- Cáncer de ovario12 estudios
- Cáncer metastásico11 estudios
- Fallo cardíaco11 estudios
- Carcinoma de células escamosas de cabeza y cuello10 estudios
- Enfermedad de obstrucción pulmonar crónica9 estudios
De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.